methyl 2-(methylamino)-2-oxoacetate | 54154-11-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-(methylamino)-2-oxoacetate
• 英文别名: Methyl (methylcarbamoyl)formate
• CAS: 54154-11-9
• 化学式: C₄H₇NO₃
• 分子量: 117.104
• InChiKey: BOUBGTOCRMNMLJ-UHFFFAOYSA-N

物化性质

• 熔点：
  78 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(methylamino)-2-oxoacetate 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 3-(2,3-二氢-5-苯并呋喃)-丙酸
  参考文献：
  名称：

  3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor

  摘要：

  A series of substituted 3-hydroxy-quinolin-2-one derivatives 6 was synthesized and evaluated as inhibitors of [H-3]-glycine and [H-3]-AMPA binding to rat cortical membranes. These compounds were generally found to be more potent ligands for the NMDA-associated glycine binding site than the AMPA receptor. Affinity for the glycine site was found to be influenced by both the electronic and steric properties associated with the C-4 substituent and the nature and pattern of substitution of the aromatic ring. The most active compound in this series, 6y, displaces [H-3]-glycine with an IC50 of 29 nM.

  DOI：

  10.1016/0960-894x(96)00031-5
• 作为产物：
  描述：

  重氮甲烷 、 3-(2,3-二氢-5-苯并呋喃)-丙酸 在 重氮甲烷 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 0.33h， 以100%的产率得到methyl 2-(methylamino)-2-oxoacetate
  参考文献：
  名称：

  Characterization of oxalic acid derivatives as new metabolites of metamizol (dipyrone) in incubated hen's egg and human

  摘要：

  Metamizol (dipyrone, 1), a widely used drug with effective analgesic and antispasmodic properties, shows severe side effects like agranulocytosis and anaphylactic shock reactions, the reasons of which are not known until today. After oral administration 1 is completely metabolized. All hitherto known metabolites have an intact pyrazolinone ring structure like the parent compound and are completely extractable from urine with polar organic solvents. However, only a fractional amount of the applied dosage can be recovered by this procedure. To clarify the reason of this deficit of unknown metabolites we followed the hypothesis of oxidative rupture of the heterocyclic ring during metabolism of 1. on the basis of former in vitro results we now were able to identify in quality three oxalic acid derivatives and one acetic acid phenylhydrazide as new metabolites of metamizol in the allantoic fluid (AF) of incubated hen's eggs as well as in human urine by means of GC-MS analysis and comparison with unequivocally synthesized authentic reference compounds. Whereas the oxamazide 7, the phenylhydrazide 8 and N-methyloxamic acid 9 are only present in trace concentrations and therefore cannot account for the deficit in the balance of metabolites, the oxalic acid monohydrazide 11 seems to be excreted in higher amount. But quantitative determination of this new metabolite would be required to answer the open questions concerning the biotransformation of metamizol and thereby to detect new facts about mode of action and side effects of this drug. (c) 2005 Elsevier B.V.All rights reserved.

  DOI：

  10.1016/j.ejps.2005.11.010

文献信息

• Development of Robust 17(R),18(S)-Epoxyeicosatetraenoic Acid (17,18-EEQ) Analogs as Potential Clinical Antiarrhythmic Agents
  作者：Adeniyi Michael Adebesin、Tim Wesser、Jonnalagadda Vijaykumar、Anna Konkel、Mahesh Paudyal、Janine Lossie、Chen Zhu、Christina Westphal、Narender Puli、Robert Fischer、Wolf-Hagen Schunck、John R. Falck

  DOI：10.1021/acs.jmedchem.9b00952

  日期：——

  due to limited oral bioavailability and metabolic stability. These ADME limitations have been addressed in an improved generation of negative chronotropes, e.g., 4 and 16, which were evaluated as potential clinical candidates.

  17（R），18（S）-环氧二十碳四烯酸（EEQ）是二十碳五烯酸（EPA）的细胞色素P450代谢产物，是新生鼠心肌细胞（NRCM）心律不齐模型中具有低纳摩尔活性的强负性变倍体。先前的研究确定草酰胺2b是一种稳定的可溶性环氧水解酶（sEH）替代品，但由于口服生物利用度和代谢稳定性有限，因此不适合用于体内应用。这些ADME局限性已通过改善负负变时剂（例如4和16）的产生得到解决，这些负变时剂被评估为潜在的临床候选药物。
• Copper-Catalysed (Diacetoxyiodo)benzene-Promoted Aerobic Esterification Reaction: Synthesis of Oxamates from Acetoacetamides
  作者：Zhiguo Zhang、Xiaolong Gao、Haifeng Yu、Guisheng Zhang、Jianming Liu

  DOI：10.1002/adsc.201800616

  日期：2018.9.3

  A copper‐catalysed (diacetoxyiodo)benzene‐promoted aerobic esterification reaction of acetoacetamides was developed for the synthesis of oxamates, which are useful precursors in synthetic organic chemistry. This practical and mild synthetic approach proceeded at 25 °C under open‐air conditions and afforded methyl 2‐oxo‐2‐(phenylamino)acetates in good to excellent yields combined with C−C σ‐bond cleavage

  开发了铜催化（二乙酰氧基碘）苯促进的乙酰乙酰胺需氧酯化反应，以合成草酸盐，草酸盐在合成有机化学中是有用的前体。这种实用且温和的合成方法在露天条件下于25°C进行，提供了具有良好或优异收率的2-氧代-2-（苯基氨基）乙酸甲酯，并带有C-Cσ-键裂解和正式的C-H氧化键功能化。提出了一种机制。
• Asymmetric Transfer Hydrogenation of α-Keto Amides; Highly Enantioselective Formation of Malic Acid Diamides and α-Hydroxyamides
  作者：Shweta K. Gediya、Vijyesh K. Vyas、Guy J. Clarkson、Martin Wills

  DOI：10.1021/acs.orglett.1c02830

  日期：2021.10.15

  The asymmetric transfer hydrogenation (ATH) of α-keto-1,4-diamides using a tethered Ru/TsDPEN catalyst was achieved in high ee. Studies on derivatives identified the structural elements which lead to the highest enantioselectivities in the products. The α-keto-amide reduction products have been converted to a range of synthetically valuable derivatives.

  使用系留的 Ru/TsDPEN 催化剂在高 ee 下实现了 α-酮基-1,4-二酰胺的不对称转移氢化（ATH）。对衍生物的研究确定了导致产品中最高对映选择性的结构元素。α-酮酰胺还原产物已转化为一系列具有合成价值的衍生物。
• [EN] NOVEL CYP-EICOSANOID DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS CYP-ÉICOSANOÏDE
  申请人：MAX DELBRÜCK CT FÜR MOLEKULARE MEDIZIN

  公开号：WO2015110262A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

  本发明涉及一般式（I）的化合物，这些化合物是由细胞色素P450（CYP）酶从ω-3（n-3）多不饱和脂肪酸（PUFAs）产生的环氧代谢产物的类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物治疗或预防与炎症、增殖、高血压、凝血、免疫功能、病理性血管生成、心力衰竭和心律失常相关的疾病和症状。
• NOVEL CYP-EICOSANOID DERIVATIVES
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：US20170008918A1

  公开（公告）日：2017-01-12

  The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for C the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

  本发明涉及一般式（I）的化合物，这些化合物是由细胞色素P450（CYP）酶从ω-3（n-3）多不饱和脂肪酸（PUFAs）产生的环氧代谢产物的类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物用于治疗或预防与炎症、增殖、高血压、凝血、免疫功能、病理性血管生成、心力衰竭和心律失常相关的疾病和症状。